Heterogeneity in Radiotherapeutic Parameter Assumptions in Cost-Effectiveness Analyses in Prostate Cancer: A Call for Uniformity

被引:0
|
作者
Butala, Anish A. [1 ]
Huang, Christina C. [2 ]
Bryant, Curtis M. [3 ]
Henderson, Randal H. [3 ]
Hoppe, Bradford S. [4 ]
Mendenhall, Nancy P. [3 ]
Vapiwala, Neha [1 ]
Vega, Raymond B. Mailhot [3 ]
机构
[1] Univ Penn, Dept Radiat Oncol, Perelman Sch Med, Philadelphia, PA USA
[2] Indiana Univ Sch Med, Dept Radiat Oncol, Indianapolis, IN USA
[3] Univ Florida, Dept Radiat Oncol, Coll Med, Gainesville, FL USA
[4] Mayo Clin, Dept Radiat Oncol, Jacksonville, FL USA
关键词
cost-effectiveness analysis; prostate cancer; radiation therapy; RISK;
D O I
10.1016/j.jval.2021.08.010
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objectives: Cost-effectiveness analyses (CEAs) may provide useful data to inform management decisions depending on the robustness of a model's input parameters. We sought to determine the level of heterogeneity in health state utility values, transition probabilities, and cost estimates across published CEAs assessing primarily radiotherapeutic management strategies in prostate cancer. Methods: We conducted a systematic review of prostate cancer CEAs indexed in MEDLINE between 2000 and 2018 comparing accepted treatment modalities across all cancer stages. Search terms included "cost effectiveness prostate," "prostate cancer cost model," "cost utility prostate," and "Markov AND prostate AND (cancer OR adenocarcinoma)." Included studies were agreed upon. A Markov model was designed using the parameter estimates from the systematic review to evaluate the effect of estimate heterogeneity on strategy cost acceptability. Results: Of 199 abstracts identified, 47 publications were reviewed and 37 were included; 508 model estimates were compared. Estimates varied widely across variables, including gastrointestinal toxicity risk (0%-49.5%), utility of metastatic disease (0.25-0.855), intensity-modulated radiotherapy cost ($21 193-$61 996), and recurrence after external-beam radiotherapy (1.5%-59%). Multiple studies assumed that different radiotherapy modalities delivering the same dose yielded varying cancer control rates. When using base estimates for similar parameters from included studies, the designed model resulted in 3 separate acceptability determinations. Conclusions: Significant heterogeneity exists across parameter estimates used to perform CEAs evaluating treatment for prostate cancer. Heterogeneity across model inputs yields variable conclusions with respect to the favorability and costeffectiveness of treatment options. Decision makers are cautioned to review estimates in CEAs to ensure they are up to date and relevant to setting and population.
引用
收藏
页码:171 / 177
页数:7
相关论文
共 50 条
  • [1] Significant Heterogeneity in Parameter Assumptions in Cost-Effectiveness Analyses in Prostate Adenocarcinoma: A Systematic Review
    Butala, A. A.
    Bryant, C. M.
    Nichols, R. C., Jr.
    Henderson, R. H.
    Hoppe, B. S.
    Mendenhall, N. P.
    Vapiwala, N.
    Vega, R. Mailhot
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : S181 - S182
  • [2] Clarifying Assumptions and Outcomes in Cost-effectiveness Analyses
    ten Haaf, Kevin
    de Koning, Harry J.
    [J]. JAMA ONCOLOGY, 2016, 2 (02) : 277 - 278
  • [3] Clarifying Assumptions and Outcomes in Cost-effectiveness Analyses Reply
    Goffin, John R.
    Flanagan, William M.
    Evans, William K.
    [J]. JAMA ONCOLOGY, 2016, 2 (02) : 278 - 279
  • [4] Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review
    Grochtdreis, Thomas
    Koenig, Hans-Helmut
    Dobruschkin, Alexander
    von Amsberg, Gunhild
    Dams, Judith
    [J]. PLOS ONE, 2018, 13 (12):
  • [5] Clinical implications of assumptions in cost-effectiveness analyses of systemic therapies for metastatic colorectal cancer.
    Degeling, Koen
    Vu, Martin
    Koffijberg, Hendrik
    Wong, Hui-Li
    Koopman, Miriam
    Gibbs, Peter
    IJzerman, Maarten J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Effectiveness and cost-effectiveness of prognostic markers in prostate cancer
    Calvert, NW
    Morgan, AB
    Catto, JWF
    Hamdy, FC
    Akehurst, RL
    Mouncey, P
    Paisley, S
    [J]. BRITISH JOURNAL OF CANCER, 2003, 88 (01) : 31 - 35
  • [7] Effectiveness and cost-effectiveness of prognostic markers in prostate cancer
    N W Calvert
    A B Morgan
    J W F Catto
    F C Hamdy
    R L Akehurst
    P Mouncey
    S Paisley
    [J]. British Journal of Cancer, 2003, 88 : 31 - 35
  • [8] COST-EFFECTIVENESS ANALYSES
    STEINBERG, EP
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (02): : 123 - 123
  • [9] A literature review of cost-effectiveness analyses of prostate-specific antigen test in prostate cancer screening
    Garg, Vishvas
    Gu, Ning Yan
    Borrego, Matthew E.
    Raisch, Dennis W.
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2013, 13 (03) : 327 - 342
  • [10] COST-EFFECTIVENESS OF AN INTERVENTION TO PERSISTENT URINARY INCONTINENCE IN PROSTATE CANCER PATIENTS: A CALL FOR SYSTEM CHANGE
    Zhang, Amy Y.
    Fu, Alex Z.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 258 - 259